a previously unexplored tumor type. These results reinforce CRB-701's potential as a differentiated treatment option for solid tumors expressing Nectin-4. The study is currently in the dose ...

During the event, the oncologist highlighted the potential of next-generation ADCs, particularly noting CRB-701's broad applicability in various tumor types beyond urothelial carcinoma.

and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood ...